Lilly gains preclinical pain program from Hydra

Eli Lilly and Co. (NYSE:LLY) acquired all assets related to Hydra Biosciences Inc.’s (Cambridge, Mass.) preclinical transient receptor potential A1 (TRPA1) antagonists for chronic pain. Financial te...